Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study

Inclusion Criteria: * \* MERKEL CELL CARCINOMA * Signed informed consent * Pathology report confirming Merkel at the time of screening * Stage II, III or IV resectable (criteria based on Merkel Cell carcinoma TNM pathologic staging AJCC UICC 8th edition) or unresectable cancers amenable to surgery if a response is elicited with neoadjuvant therapy * ≥ 18 years of age * Genomics of the cancer attempted * Description of planned surgical resection by surgeon * Planned treatment with immunotherapy. Possible Beacon plan entitled OP NIVOLUMAB IPILIMUMAB NEUROENDOCRINE (PRL 8149) * 2 cycles will be given prior to surgery (=12 weeks). * MUCOSAL MELANOMA * Signed informed consent * Pathology report confirming mucosal melanoma at the time of screening * Stage III or IV resectable (TNM pathologic staging AJCC UICC 8th edition) or unresectable cancers amenable to surgery if a response is elicited with neoadjuvant therapy * ≥ 18 years of age * Genomics of the cancer attempted * Description of planned surgical resection by surgeon * SOC (standard of care) treatment planned with immunotherapy Possible Beacon plan entitled OP NIVOLUMAB IPILIMUMAB -\> NIVOLUMAB Q4 WEEK MAINTENANCE MELANOMA 4 cycles will be given prior to surgery (=12 weeks) * BASAL CELL CARCINOMA * Signed informed consent * Pathology report confirming basal cell carcinoma with subtype at the time of screening * Resectable tumor of any stage, or unresectable tumor that could…